A
|
2027 Non-preferred Part B Drugs Subject to Step Therapy*
|
2027 Preferred Part B Drugs*
|
|
Denosumab Products**
Prolia & Xgeva (denosumab)
Wyost & Jubbonti (denosumab-bbdz)
Stoboclo & Osenvelt (denosumab-bmwo)
Jubereq & Osvyrti (denosumab-desu)
Aukelso & Bosaya (denosumab-kyqq)
Ospomyv (denosumab-dssb)
|
Enoby & Xtrenbo (denosumab-qbde)
Bildyos & Bilprevda (denosumab-nxxp)
|
|
Bevacizumab Products (oncology)
Avastin (bevacizumab)
|
Mvasi (bevacizumab-awwb)
Vegzelma (bevacizumab-adcd)
|
|
Hyaluronic Acid Derivatives**
Hyalgan, Supartz, Visco-3 (sodium hyaluronate)
Euflexxa, Durolane (sodium hyaluronate)
Monovisc, Hymovisc (hyaluronan)
Hyalgan, Genvisc 850 (sodium hyaluronate)
Triluron, Trivisc, Synojoynt (sodium hyaluronate)
|
Orthovisc (hyaluronan)
Synvisc, Synvisc-One (hylan polymers A and B)
|
|
Tocilizumab Products
Actemra (tocilizumab)
|
Tyenne (tocilizumab-aazg)
|
|
Ustekinumab Products**
Stelara (ustekinumab)
|
Pyzchiva (ustekinumab-ttwe)
Steqyma (ustekinumab-stba)
|
* Step therapy prescription drug list is subject to change at any time.
** Provider Note: A valid NDC is required when requesting authorization, ordering, and administering these products.